Skip to main content
SpringerLink
Log in

More effective radioimmunotherapy on the way for NHL?

  • Newsletter Article
  • Published:
Inpharma Weekly

Abstract

A unique new radioimmunotherapeutic conjugate, 131I anti-B1 antibody [B1, ‘Bexxar’; Coulter Pharmaceuticals], appears to offer an effective, well tolerated, and less costly approach for the treatment of patients with low-grade, and transformed low-grade, B-cell non-Hodgkin’s lymphoma (NHL). The latest developments with this targeted therapy approach were presented at the 39th Annual Meeting & Exposition of the American Society of Hematology [ San Diego, US; December 1997 ].

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Authors
  1. Larry Prescott
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Prescott, L. More effective radioimmunotherapy on the way for NHL?. Inpharma Wkly. 1121, 9–10 (1998). https://doi.org/10.2165/00128413-199811210-00016

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128413-199811210-00016

Search

Navigation